thiazoles has been researched along with Sclerosis, Systemic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Betkier-Lipińska, K; Cwetsch, A; Góra-Tybor, J; Ryczek, R | 1 |
| Dreyfus, DH; Faggioni, A; Farina, A; Farina, GA; Lacconi, V; Lenna, S; Morrone, S; Peruzzi, G; Quarta, S; Rosato, E; Trojanowska, M; Vestri, AR; York, M | 1 |
| Distler, JH; Distler, O | 1 |
| Au, K; Clements, PJ; Furst, DE; Khanna, D; Tashkin, DP | 1 |
| Beyer, C; Distler, JH; Distler, O | 1 |
| Akhmetshina, A; Axmann, R; Dees, C; Distler, JH; Distler, O; Gay, S; Jüngel, A; Maurer, B; Pileckyte, M; Schett, G; Zwerina, J | 1 |
2 review(s) available for thiazoles and Sclerosis, Systemic
| Article | Year |
|---|---|
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Fibrosis; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides; Thiazoles | 2008 |
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Benzamides; Cyclophosphamide; Dasatinib; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interleukin-13; Lung Diseases, Interstitial; Mycophenolic Acid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Respiratory Function Tests; Scleroderma, Systemic; Thiazoles; Treatment Outcome | 2009 |
4 other study(ies) available for thiazoles and Sclerosis, Systemic
| Article | Year |
|---|---|
[Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
Topics: Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Thiazoles | 2013 |
Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
Topics: Adult; Aged; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Epstein-Barr Virus Infections; Female; Gene Expression; Gene Expression Profiling; Herpesvirus 4, Human; Host-Pathogen Interactions; Humans; Immunity, Innate; Male; Middle Aged; Monocytes; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Systemic; Thiazoles; Toll-Like Receptor 8; Virus Replication; Young Adult | 2017 |
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles | 2010 |
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
Topics: Adult; Age of Onset; Aged; Biopsy; Cells, Cultured; Dasatinib; Fibroblasts; Humans; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction; Skin; Thiazoles | 2008 |